PortalPublikationenMetastatic Colorectal Cancer Outcomes by Age Among ARCAD Fir...

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

Standard

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. / McCleary, Nadine J; Harmsen, William S; Haakenstad, Ellana; Cleary, James M; Meyerhardt, Jeffrey A; Zalcberg, John; Adams, Richard; Grothey, Axel; Sobrero, Alberto F; Van Cutsem, Eric; Goldberg, Richard M; Peeters, Marc; Tabernero, Josep; Seymour, Matt; Saltz, Leonard B; Giantonio, Bruce J; Arnold, Dirk; Rothenberg, Mace L; Koopman, Miriam; Schmoll, Hans-Joachim; Pitot, Henry C; Hoff, Paulo M; Tebbutt, Niall; Masi, Gianluca; Souglakos, John; Bokemeyer, Carsten; Heinemann, Volker; Yoshino, Takayuki; Chibaudel, Benoist; deGramont, Aimery; Shi, Qian; Lichtman, Stuart M.

in: JNCI CANCER SPECT, Jahrgang 6, Nr. 2, pkac014, 02.03.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

McCleary, NJ, Harmsen, WS, Haakenstad, E, Cleary, JM, Meyerhardt, JA, Zalcberg, J, Adams, R, Grothey, A, Sobrero, AF, Van Cutsem, E, Goldberg, RM, Peeters, M, Tabernero, J, Seymour, M, Saltz, LB, Giantonio, BJ, Arnold, D, Rothenberg, ML, Koopman, M, Schmoll, H-J, Pitot, HC, Hoff, PM, Tebbutt, N, Masi, G, Souglakos, J, Bokemeyer, C, Heinemann, V, Yoshino, T, Chibaudel, B, deGramont, A, Shi, Q & Lichtman, SM 2022, 'Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials', JNCI CANCER SPECT, Jg. 6, Nr. 2, pkac014. https://doi.org/10.1093/jncics/pkac014

APA

McCleary, N. J., Harmsen, W. S., Haakenstad, E., Cleary, J. M., Meyerhardt, J. A., Zalcberg, J., Adams, R., Grothey, A., Sobrero, A. F., Van Cutsem, E., Goldberg, R. M., Peeters, M., Tabernero, J., Seymour, M., Saltz, L. B., Giantonio, B. J., Arnold, D., Rothenberg, M. L., Koopman, M., ... Lichtman, S. M. (2022). Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI CANCER SPECT, 6(2), [pkac014]. https://doi.org/10.1093/jncics/pkac014

Vancouver

McCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J et al. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI CANCER SPECT. 2022 Mär 2;6(2). pkac014. https://doi.org/10.1093/jncics/pkac014

Bibtex

@article{484177b61b724c70b0b2f807ed27e6e6,
title = "Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials",
abstract = "BACKGROUND: We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials.METHODS: Associations between clinical and disease characteristics, time to initial progression, and rate of receipt of second-line therapy were evaluated. TTP and overall survival (OS) were compared between older and younger adults in first- and second-line trials by Cox regression, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites and presence of metastasis in the lung, liver, or peritoneum. All statistical tests were 2-sided.RESULTS: Older adults comprised 16.4% of patients on first-line trials (870 total older adults aged >70 years; 4419 total younger adults aged ≤70 years, on first-line trials). Older adults and those with Eastern Cooperative Oncology Group Performance Status >0 were less likely to receive second-line therapy than younger adults. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariable analysis (odds ratio = 1.11, 95% confidence interval = 1.02 to 1.21, P = .01). Older and younger adults enrolled in second-line trials experienced similar median TTP and median OS (median TTP = 5.1 vs 5.2 months, respectively; median OS = 11.6 vs 12.4 months, respectively).CONCLUSIONS: Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy.",
author = "McCleary, {Nadine J} and Harmsen, {William S} and Ellana Haakenstad and Cleary, {James M} and Meyerhardt, {Jeffrey A} and John Zalcberg and Richard Adams and Axel Grothey and Sobrero, {Alberto F} and {Van Cutsem}, Eric and Goldberg, {Richard M} and Marc Peeters and Josep Tabernero and Matt Seymour and Saltz, {Leonard B} and Giantonio, {Bruce J} and Dirk Arnold and Rothenberg, {Mace L} and Miriam Koopman and Hans-Joachim Schmoll and Pitot, {Henry C} and Hoff, {Paulo M} and Niall Tebbutt and Gianluca Masi and John Souglakos and Carsten Bokemeyer and Volker Heinemann and Takayuki Yoshino and Benoist Chibaudel and Aimery deGramont and Qian Shi and Lichtman, {Stuart M}",
note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press.",
year = "2022",
month = mar,
day = "2",
doi = "10.1093/jncics/pkac014",
language = "English",
volume = "6",
journal = "JNCI CANCER SPECT",
issn = "2515-5091",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

AU - McCleary, Nadine J

AU - Harmsen, William S

AU - Haakenstad, Ellana

AU - Cleary, James M

AU - Meyerhardt, Jeffrey A

AU - Zalcberg, John

AU - Adams, Richard

AU - Grothey, Axel

AU - Sobrero, Alberto F

AU - Van Cutsem, Eric

AU - Goldberg, Richard M

AU - Peeters, Marc

AU - Tabernero, Josep

AU - Seymour, Matt

AU - Saltz, Leonard B

AU - Giantonio, Bruce J

AU - Arnold, Dirk

AU - Rothenberg, Mace L

AU - Koopman, Miriam

AU - Schmoll, Hans-Joachim

AU - Pitot, Henry C

AU - Hoff, Paulo M

AU - Tebbutt, Niall

AU - Masi, Gianluca

AU - Souglakos, John

AU - Bokemeyer, Carsten

AU - Heinemann, Volker

AU - Yoshino, Takayuki

AU - Chibaudel, Benoist

AU - deGramont, Aimery

AU - Shi, Qian

AU - Lichtman, Stuart M

N1 - © The Author(s) 2022. Published by Oxford University Press.

PY - 2022/3/2

Y1 - 2022/3/2

N2 - BACKGROUND: We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials.METHODS: Associations between clinical and disease characteristics, time to initial progression, and rate of receipt of second-line therapy were evaluated. TTP and overall survival (OS) were compared between older and younger adults in first- and second-line trials by Cox regression, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites and presence of metastasis in the lung, liver, or peritoneum. All statistical tests were 2-sided.RESULTS: Older adults comprised 16.4% of patients on first-line trials (870 total older adults aged >70 years; 4419 total younger adults aged ≤70 years, on first-line trials). Older adults and those with Eastern Cooperative Oncology Group Performance Status >0 were less likely to receive second-line therapy than younger adults. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariable analysis (odds ratio = 1.11, 95% confidence interval = 1.02 to 1.21, P = .01). Older and younger adults enrolled in second-line trials experienced similar median TTP and median OS (median TTP = 5.1 vs 5.2 months, respectively; median OS = 11.6 vs 12.4 months, respectively).CONCLUSIONS: Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy.

AB - BACKGROUND: We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials.METHODS: Associations between clinical and disease characteristics, time to initial progression, and rate of receipt of second-line therapy were evaluated. TTP and overall survival (OS) were compared between older and younger adults in first- and second-line trials by Cox regression, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites and presence of metastasis in the lung, liver, or peritoneum. All statistical tests were 2-sided.RESULTS: Older adults comprised 16.4% of patients on first-line trials (870 total older adults aged >70 years; 4419 total younger adults aged ≤70 years, on first-line trials). Older adults and those with Eastern Cooperative Oncology Group Performance Status >0 were less likely to receive second-line therapy than younger adults. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariable analysis (odds ratio = 1.11, 95% confidence interval = 1.02 to 1.21, P = .01). Older and younger adults enrolled in second-line trials experienced similar median TTP and median OS (median TTP = 5.1 vs 5.2 months, respectively; median OS = 11.6 vs 12.4 months, respectively).CONCLUSIONS: Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy.

U2 - 10.1093/jncics/pkac014

DO - 10.1093/jncics/pkac014

M3 - SCORING: Journal article

C2 - 35603849

VL - 6

JO - JNCI CANCER SPECT

JF - JNCI CANCER SPECT

SN - 2515-5091

IS - 2

M1 - pkac014

ER -